Trial Information

Summary: Biomarkers, Breast Density, and Risk Reduction Perspectives

You have been invited to participate in this research study because you are pre-menopausal with an increased risk of breast cancer on the basis of a germline BRCA mutation or strong family history of breast cancer. Two groups of women may participate: Women who plan to proceed with risk reduction bilateral mastectomy shortly after the completion of the study, and women who will continue surveillance. The purpose of this study is to evaluate the effect on breast density, on perspectives about risk reduction options, and on quality of life of 6-10 months of treatment with a nasal spray containing the investigational drug deslorelin, plus partial replacement of estrogen and testosterone with a second nasal spray and of progesterone given as a pill. The effects on breast tissue will be evaluated through imaging studies and laboratory studies of biopsy samples. Your participation in this study is expected to last approximately 10 months.

Patient Inclusion/Exclusion Criteria:

- See http://clinicaltrials.coh.org for additional information.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: July 7, 2008 at 2:31:10 PM